Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Active substance : rifampicine
  • Producer : industriels
  • Topics : Heart diseases
Filter
Topic
  • Economics and public health (1)
  • Plus ...
    • Screening, prevention (1)
  • Diseases and conditions (1)
  • Plus ...
    • Infectious diseases (1)
    • Plus ...
      • Bacterial infections (1)
    • Dental and mouth diseases (1)
    • Plus ...
      • Dental and mouth diseases - miscellaneous (1)
    • Heart diseases (1)
    • Plus ...
      • Endocarditis (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Date
  • This year (1)
Fabricant
  • inconnu (1)
  • industriels (1)
Langue
  • Français (1)
Substance active
  • acide clavulanique (1)
  • acide fusidique (1)
  • alcool (1)
  • amikacine (1)
  • amoxicilline (1)
  • ceftriaxone (1)
  • ciprofloxacine (1)
  • clarithromycine (1)
  • clindamycine (1)
  • colchicine (1)
  • daptomycine (1)
  • digluconate de chlorhexidine (1)
  • doxycycline (1)
  • fluindione (1)
  • halothane (1)
  • povidone (1)
  • pristinamycine (1)
  • propofol (1)
  • rifampicine (1)
  • simvastatine (1)
  • sodium (1)
  • vancomycine (1)
More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 1 result

  • Oral and dental care of patients at risk of infective endocarditis

    Practice guidelines - Posted on 29/11/2021 - Mis à jour le 21/2/2025
    Download abstract
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
t69MynJLVqHcGVSK